SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2023-02-23** | Period of Report: **2023-02-21** SEC Accession No. 0000898432-23-000125

(HTML Version on secdatabase.com)

REPORTING OWNER

Hwang Kuk Hyoun

CIK:1953660

Type: 4 | Act: 34 | File No.: 001-41390 | Film No.: 23660164

Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004

ISSUER

Bellevue Life Sciences Acquisition Corp.

CIK:1840425| IRS No.: 845052822 | State of Incorp.:DE | Fiscal Year End: 1231 SIC: 6770 Blank checks

Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 Business Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 425-635-7700

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL												
OMB Number:	3235-0287											
Expires:	02/28/2011											
Estimated average b	ourden											
hours per response	0.5											

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres Hwang Kuk H	, ,	son <u>*</u>	2. Issuer Name and Ticker or Trading Symbol Bellevue Life Sciences Acquisition Corp. [BLAC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X DirectorX 10% OwnerX Officer (give title below) below)				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/21/2023	below) Delow) Chief Executive Officer				
10900 NE 4TH S	TREET, SUITE	2300						
BELLEVUE, WA	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing (Check applicable line)X Form Filed by One Reporting Person Form Filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/Year)	2A. Deemed Execution Date, if			' '			5. Amount of Securities Beneficially Owned Following	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		any (Month/ Day/Year)	Code	V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)		
Common Stock	02/21/2023		<u>J</u> (2)		225,000	A	\$ 0	2,025,000 (1) (2)	I	By Bellevue Global Life Sciences Investors LLC	
Common Stock	02/21/2023		<u>J</u> (<u>3</u>)		4,500	D	\$ 0	2,020,500 (1) (3)	I	By Bellevue Global Life Sciences Investors LLC	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/ Day/Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transa Code (Instr. 8	of Deriv Secu Acqu (A) o Dispo of (D (Instr	rative rities ired r osed)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	4, an (A)	,	Date Exercisable	Expiration	Title	Amount or Number				

		 	 				_		_
l						۱.		l	
l						I OT		l	
l						۱ ـ .		l	
l						Shares		l	

Explanation of Responses:

- 1. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.
- 2. Represents the shares that will no longer be forfeited by the Sponsor as a result of the underwriters exercising the over-allotment option in full.
- 3. Represents an additional 4,500 shares that were transferred from the Sponsor to the underwriters as a result of the underwriters exercising the overallotment option in full.

Signatures

/s/ Kuk Hyoun Hwang

02/23/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.